EPCR, Human, mAb RCR-252, FITC

Catalog #: HM2145F
Quantity: 100 µg

Original supplier of innate immunity products since 1994.

Our commitment to quality: Read more!

Contact our support team for more product information.

Can't find your application for a product? Request a sample!

The monoclonal antibody RCR-252 recognizes human endothelial protein C receptor (EPCR), a highly glycosylated type I transmembrane protein of 221-amino-acids. These amino acids comprise an extracellular domain, a 25-aa transmembrane domain, and a short (3 aa) intracytoplasmic sequence coding for an ~46 kDa protein. Deglycosylation will reduce the protein mass to 25 kDa. EPCR is expressed strongly on the endothelial cells of arteries and veins in heart and lung, less intensely in capillaries in the lung and skin, and not at all in the endothelium of small vessels of the liver and kidney.
EPCR is the receptor for protein C, a key player in the anticoagulation pathway. The protein C anticoagulant pathway serves as a major system for controling thrombosis, limiting inflammatory responses, and potentially decreasing endothelial cell apoptosis in response to inflammatory cytokines and ischemia. The essential components of the pathway include thrombin, thrombomodulin, the endothelial cell protein C receptor (EPCR), protein C and protein S. The pathway is initiated when thrombin binds to thrombomodulin on the surface of endothelium. EPCR augments protein C activation by binding protein C and presenting it to the thrombin-thrombomodulin activation complex. Activated protein C (aPC) retains its ability to bind EPCR, and this complex appears to be involved in some of the cellular signaling mechanisms that down-regulate inflammatory cytokine formation (TNF, IL-6). EPCR is shed from the vasculature by inflammatory mediators and thrombin. EPCR binds to activated neutrophils in a process that involves proteinase 3 and Mac-1. Furthermore, EPCR can undergo translocation from the plasma membrane to the nucleus.
EPCR can be cleaved to release a soluble form (sEPCR) in the circulation. This sEPCR is detected as a single species of 43 kDa, resulting from shedding of membrane EPCR by the action of a metalloprotease,- which is stimulated by thrombin and by some inflammatory mediators. Soluble EPCR binds PC and aPC with similar affinity, but its binding to aPC inhibits the anticoagulant activity of aPC by blocking its binding to phospholipids and by abrogating its ability to inactivate factor Va. sEPCR- can be detected in plasma. In normal persons, sEPCR is present in levels of 83.6 +/- 17.2 ng/ml. Elevated levels of sEPCR are positively correlated to a higher risk for thrombosis. Furthermore, a haplotype (A3 allele) has been linked to elevated levels of sEPCR (264 +/-174 ng/ml).


Catalog number HM2145F
Product type Monoclonal antibodies
Quantity 100 µg
Formulation 1 ml (100 μg/ml) 0.2 μm filtered protein G purified FITC conjugated antibody solution in PBS, containing 1.0% bovine serum and 0.02% sodium azide.
Conjugate FITC
Immunogen Human EPCR-positive RE-1 cells
Isotype Rat IgG1
Species Human
Alias Activated protein C receptor, CD201, Endothelial cell protein C receptor
Gene name: PROCR
Storage and stability Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
Precautions For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Disease Cardiology and metabolism
  • Application:
    FC, FS, IP, W
  • Application Notes:
    FC: Antibody RCR-252 stains the extracellular domain of human EPCR. As positive control RE-1 cells were used and as negative control N1 cells. (Ref.1)
    W: A non-reduced sample treatment was used. The observed band size is 50 kDa (Ref.5).
    FS: Antibody RCR-252 functions as blocking antbody. It ablates APC binding to EPCR and blocks APC-mediated signaling. The antibody was functionally tested by pretreatment of cells with 10-25  µg/ml RCR-252 (Ref.1-4).
  • Positive Control:
    RE-1 (rat 3Y1 fibroblasts stably transfected with human EPCR.
  • Negative Control:
    N1 cells
  • Use:
    Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
1. Ye, X et al; The endothelial cell protein C receptor (EPCR) functions as a primary receptor for protein C activation on endothelial cells in arteries, veins, and capillaries. Biochem Biophys Res Commun 1999, 259: 671
2. Dömötör, E et al; Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003, 101: 4797
3. Sturn, D et al; Expression and function of the endothelial protein C receptor in human neutrophils. Blood 2003, 102: 1499
4. Finigan, J et al; Activated protein C mediates novel lung endothelial barriere enhancement. J Biol Chem 2005, 280: 17286
5. Bae J et al; Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. PNAS 2006, 104: 2867
You may also be interested in the following product(s)
Product description
Catalog #